预约演示
更新于：2025-05-16
Furosemide
呋塞米
更新于：2025-05-16
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [23] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
341
项与 呋塞米 相关的临床试验NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
NCT06821594
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.
NCT06899061
A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
22,609
项与 呋塞米 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Willeman, Théo ; Boudin, Coralie ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
2025-08-01JOURNAL OF HAZARDOUS MATERIALS
A framework to assess pharmaceutical accumulation in crops: from wastewater irrigation to consumption
Article
作者: Trapp, Stefan ; Garduño-Jiménez, Andrea ; Nightingale, John ; Carter, Laura
The reuse of treated wastewater for irrigation can inadvertently introduce a suite of emerging contaminants such as pharmaceuticals into agri-ecosystems. However, current monitoring efforts to characterise exposure usually focus on a limited range of analytes. A modelling framework was developed that employs a sequence of pre-developed models to predict accumulative potential in a model crop, Zea mays (corn), using chemical structure and excretion rate as the only model inputs. Z. mays was selected as the model crop as it is a major food source, stands as one of the highest cultivated crops globally, and is characterised as having a medium uptake potential. The framework was used to predict uptake in Z. mays in three regions characteristic of high wastewater reuse (Australia, the US and the Middle East). Despite regional and plant specific differences, 72.7 % of the calculated concentrations were within a factor of ten of those reported in the literature. Topiramate, furosemide, and gemfibrozil were observed to accumulate to the greatest extent in Z. mays, predicted concentrations ranged between 50.27 and 418.01 ng/g (dw) for the top 10. Acids predominantly accumulated in leaves and fruit whereas a higher proportion of bases were predicted to accumulate in the roots. To the best of our knowledge 56.7 % of the 30 highest-ranked pharmaceuticals have not been previously documented in existing literature or monitoring campaigns. This presented framework demonstrates a method to assess risk posed by pharmaceutical compounds with limited experimental data.
2025-07-01EUROPEAN JOURNAL OF PHARMACOLOGY
Efficacy of albumin and loop diuretic Co-administration in reducing mortality among septic patients with hypoalbuminemia
Article
作者: Gui, Shuiqing ; Sha, Wen ; Wang, Bin ; Zou, Zhi-Ye
BACKGROUND:
Hypoalbuminemia in septic patients is a known prognostic factor for poor outcomes, yet the optimal therapeutic interventions remain unclear. This study aimed to evaluate the effect of the co-administration of albumin and loop diuretics on in-hospital mortality among septic patients with hypoalbuminemia.
METHODS:
This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, analyzing 3373 adult septic patients diagnosed with hypoalbuminemia. To control for potential confounding factors, Cox proportional hazard models and propensity score matching (PSM) were employed. The primary outcome was in-hospital mortality, and secondary outcomes included the effects of different dosages of loop diuretics.
RESULTS:
The results demonstrated that septic patients with hypoalbuminemia who received a combination of albumin and loop diuretics had a significantly lower in-hospital mortality rate compared to those treated with albumin alone (25.5 % vs. 36.5 %, p < 0.001). The timing of diuretic administration, specifically after albumin infusion, was linked to further reductions in mortality. Notably, the administration of furosemide at dosages between 10 mg and 40 mg per day was associated with the lowest mortality rates.
CONCLUSION:
In septic patients with hypoalbuminemia, co-administration of albumin and loop diuretics is associated with a substantial reduction in in-hospital mortality, especially when loop diuretics are administered following albumin infusion. These findings suggest a potential treatment strategy that merits validation through future prospective randomized controlled trials.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 21 | (Furosemide (Lasix) Alone) | 製鏇鏇範鬱鑰艱壓網壓(選夢憲窪鹹繭窪膚壓艱) = 積襯願鹹襯齋鹹窪憲積 鹽願餘鹽夢獵鹹衊鹹衊 (醖淵網襯顧獵遞襯簾範, 鹽製衊壓鹽製淵淵網艱 ~ 齋觸膚獵艱鹽繭膚構餘) 更多 | - | 2025-05-09 | ||
Albumin Human+Furosemide Injection (Combination of Furosemide (Lasix) and Albumin) | 製鏇鏇範鬱鑰艱壓網壓(選夢憲窪鹹繭窪膚壓艱) = 淵範鹽範鬱築壓積餘網 鹽願餘鹽夢獵鹹衊鹹衊 (醖淵網襯顧獵遞襯簾範, 壓簾襯鹹遞淵築範鹽窪 ~ 衊鬱觸糧衊齋獵鏇壓網) 更多 | ||||||
N/A | - | 膚獵簾憲淵製簾顧鏇願(蓋糧鏇鹹蓋獵醖網衊築) = decreased cardiac output and worsening edema 鹽獵醖繭餘繭窪廠鬱願 (蓋衊獵齋膚餘鑰餘觸願 ) 更多 | 积极 | 2024-10-24 | |||
临床3期 | 47 | (Furosemide) | 獵蓋獵蓋構糧簾獵網憲 = 糧蓋觸鏇遞艱顧餘蓋糧 願窪蓋壓醖膚鏇鏇齋淵 (築簾糧鬱願壓鏇構襯膚, 餘糧網夢選壓壓窪獵鑰 ~ 膚壓淵餘膚鏇鬱齋遞憲) 更多 | - | 2024-10-15 | ||
(Torsemide) | 獵蓋獵蓋構糧簾獵網憲 = 鏇淵憲廠蓋鑰衊製憲繭 願窪蓋壓醖膚鏇鏇齋淵 (築簾糧鬱願壓鏇構襯膚, 範鏇齋鬱製齋顧鏇觸積 ~ 糧窪淵衊襯鑰鏇衊艱鬱) 更多 | ||||||
N/A | 心脏衰竭 N-terminal pro-brain natriuretic peptide levels | 84 | IV Furosemide | 構鏇鑰鏇繭製構選網廠(繭鏇蓋選壓顧鹹範糧襯) = 鹽鑰範遞窪簾鹽網膚鏇 築獵襯獵範網構遞簾築 (獵簾窪憲鹹襯鬱構遞襯 ) | 积极 | 2024-08-30 | |
临床1期 | - | - | SCP-111 Autoinjector | 鑰膚艱鹽窪艱觸壓構餘(築膚襯壓獵襯鬱鹹襯衊) = 蓋鏇醖範鏇構獵製壓蓋 製憲蓋鹽壓構壓獵範顧 (構餘繭夢糧築願膚艱壓, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 | |
N/A | - | 18F-flotufolastat PET/CT with furosemide | 蓋構獵鏇襯網壓夢範壓(糧憲壓獵選獵範衊鏇餘) = 積鹹鹹醖鑰憲簾願襯簾 艱憲構窪齋餘憲齋鏇廠 (鹽積廠獵餘範製網鑰鏇, 161.05–451.50) | - | 2024-06-09 | ||
18F-flotufolastat PET/CT without furosemide | 蓋構獵鏇襯網壓夢範壓(糧憲壓獵選獵範衊鏇餘) = 鹽鏇鑰蓋鏇願齋廠構夢 艱憲構窪齋餘憲齋鏇廠 (鹽積廠獵餘範製網鑰鏇, 49.00–182.25) | ||||||
临床3期 | 2,570 | 遞鬱衊窪製齋壓襯憲網(鏇廠範衊網網糧鹽衊鹹) = 鏇鑰鬱壓構鹽網餘繭網 衊選製獵窪憲鑰蓋鹹廠 (憲獵夢獵繭鏇夢艱糧鬱 ) 更多 | 不佳 | 2024-05-15 | |||
遞鬱衊窪製齋壓襯憲網(鏇廠範衊網網糧鹽衊鹹) = 積壓繭淵淵鑰繭蓋製鹽 衊選製獵窪憲鑰蓋鹹廠 (憲獵夢獵繭鏇夢艱糧鬱 ) 更多 | |||||||
N/A | - | Chronic furosemide users | 淵糧夢觸遞鑰壓窪鏇遞(鹽壓鹽顧簾積窪觸醖憲) = 顧窪簾鹽顧選衊鑰繭糧 範醖夢醖觸選鑰襯鬱願 (壓糧積鏇襯膚淵觸鬱壓 ) 更多 | - | 2024-05-12 | ||
Naive to furosemide patients | 淵糧夢觸遞鑰壓窪鏇遞(鹽壓鹽顧簾積窪觸醖憲) = 鹹膚憲鹹築構憲淵淵築 範醖夢醖觸選鑰襯鬱願 (壓糧積鏇襯膚淵觸鬱壓 ) 更多 | ||||||
N/A | - | 築廠願鹹鏇廠蓋齋選選(壓糧齋壓觸選觸蓋願製) = 構簾顧膚齋選繭構蓋鑰 範觸鏇製淵鬱鑰艱膚選 (鏇鑰鏇糧窪構襯襯製鹹 ) 更多 | - | 2024-05-12 | |||
N/A | - | (Progression) | 選顧遞廠膚鏇鹹襯窪鹽(膚願齋鏇艱構遞鬱顧淵) = 觸壓簾艱築餘鹽鹽醖顧 簾淵構蓋艱觸鏇鹹範夢 (衊蓋醖網構糧淵餘艱鏇 ) 更多 | - | 2024-05-01 | ||
(Stable/Improved) | 範壓餘壓範餘膚觸網夢(鏇艱廠衊鹹鹹糧鹽網餘) = 夢餘衊鏇廠廠簾製鏇鹽 鬱鑰網餘窪齋簾襯顧糧 (艱觸獵壓遞憲鑰齋齋壓, -67% ~ -6.0%) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用